The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Longer-term follow-up of prophylactic tocilizumab for the reduction of CRS in the MajesTEC-1 trial
Niels Van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, discusses the longer-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) following teclistamab administration in the Phase I/II MajesTEC-1 study (NCT04557098). Prophylactic tocilizumab significantly reduced CRS rate (74% to 25%) without compromising the efficacy and safety profile of teclistamab therapy. These findings will allow for improved treatment of patients with teclistamab in the outpatient setting. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
